Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)
Status:
Terminated
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase III, multicenter, global, open-label, single-arm, retreatment study of an
investigational drug called galiximab in combination with an approved drug called rituximab
in subjects with relapsed or refractory, follicular NHL who demonstrated a response on Study
114-NH-301 with a time-to-progression >=6 months.